Christopher J Portier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2851776/publications.pdf

Version: 2024-02-01

70961 66788 7,128 179 41 78 citations h-index g-index papers 189 189 189 6615 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Insights from application of a hierarchical spatio-temporal model to an intensive urban black carbon monitoring dataset. Atmospheric Environment, 2022, 277, 119069.	1.9	3
2	Association between traffic related air pollution exposure and direct health care costs in Northern California. Atmospheric Environment, 2022, 287, 119271.	1.9	1
3	Achieving a High Level of Protection from Pesticides in Europe: Problems with the Current Risk Assessment Procedure and Solutions. European Journal of Risk Regulation, 2020, 11, 450-480.	0.8	30
4	A comprehensive analysis of the animal carcinogenicity data for glyphosate from chronic exposure rodent carcinogenicity studies. Environmental Health, 2020, 19, 18.	1.7	42
5	Characterizing Elevated Urban Air Pollutant Spatial Patterns with Mobile Monitoring in Houston, Texas. Environmental Science &	4.6	41
6	Concordance between sites of tumor development in humans and in experimental animals for 111 agents that are carcinogenic to humans. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2019, 22, 203-236.	2.9	22
7	Mapping Air Pollution with Google Street View Cars: Efficient Approaches with Mobile Monitoring and Land Use Regression. Environmental Science & Envir	4.6	103
8	High-resolution mapping of traffic related air pollution with Google street view cars and incidence of cardiovascular events within neighborhoods in Oakland, CA. Environmental Health, 2018, 17, 38.	1.7	78
9	Elucidating environmental dimensions of neurological disorders and disease: Understanding new tools from federal chemical testing programs. Science of the Total Environment, 2017, 593-594, 634-640.	3.9	2
10	High-Resolution Air Pollution Mapping with Google Street View Cars: Exploiting Big Data. Environmental Science & Environmental	4.6	474
11	Re: Tarazona et al. (2017): Glyphosate toxicity and carcinogenicity: a review of the scientific basis of the European Union assessment and its differences with IARC. doi: 10.1007/s00204-017-1962-5. Archives of Toxicology, 2017, 91, 3195-3197.	1.9	14
12	Comparison of Points of Departure for Health Risk Assessment Based on High-Throughput Screening Data. Environmental Health Perspectives, 2017, 125, 623-633.	2.8	18
13	Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of Carcinogenesis. Environmental Health Perspectives, 2016, 124, 713-721.	2.8	415
14	The Next Generation of Risk Assessment Multi-Year Study—Highlights of Findings, Applications to Risk Assessment, and Future Directions. Environmental Health Perspectives, 2016, 124, 1671-1682.	2.8	74
15	The Use of Signal-Transduction and Metabolic Pathways to Predict Human Disease Targets from Electric and Magnetic Fields Using in vitro Data in Human Cell Lines. Frontiers in Public Health, 2016, 4, 193.	1.3	3
16	Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). Journal of Epidemiology and Community Health, 2016, 70, 741-745.	2.0	138
17	A simple procedure for estimating pseudo risk ratios from exposure to non-carcinogenic chemical mixtures. Archives of Toxicology, 2016, 90, 513-523.	1.9	2
18	Environmental Predictors of US County Mortality Patterns on a National Basis. PLoS ONE, 2015, 10, e0137832.	1.1	6

#	Article	lF	CITATIONS
19	Building a Robust 21st Century Chemical Testing Program at the U.S. Environmental Protection Agency: Recommendations for Strengthening Scientific Engagement. Environmental Health Perspectives, 2015, 123, 1-5.	2.8	17
20	Inconclusive Findings: Now You See Them, Now You Don't!. Environmental Health Perspectives, 2014, 122, A36.	2.8	10
21	Blood lead level association with lower body weight in NHANES 1999–2006. Toxicology and Applied Pharmacology, 2013, 273, 516-523.	1.3	67
22	Evaluation of Biomonitoring Data from the CDC National Exposure Report in a Risk Assessment Context: Perspectives across Chemicals. Environmental Health Perspectives, 2013, 121, 287-294.	2.8	126
23	Biological Networks for Predicting Chemical Hepatocarcinogenicity Using Gene Expression Data from Treated Mice and Relevance across Human and Rat Species. PLoS ONE, 2013, 8, e63308.	1.1	16
24	Gene Expression Networks. Methods in Molecular Biology, 2013, 930, 165-178.	0.4	2
25	Signal-To-Noise Crossover Dose: Sand et al. Respond. Environmental Health Perspectives, 2012, 120, .	2.8	1
26	Adverse effects in risk assessment: Modeling polychlorinated biphenyls and thyroid hormone disruption outcomes in animals and humans. Environmental Research, 2012, 116, 74-84.	3.7	8
27	Upstream adverse effects in risk assessment: A model of polychlorinated biphenyls, thyroid hormone disruption and neurological outcomes in humans. Environmental Research, 2012, 117, 90-99.	3.7	19
28	Comprehensive Environmental Public Health. Public Health Reports, 2011, 126, 3-6.	1.3	1
29	A Signal-to-Noise Crossover Dose as the Point of Departure for Health Risk Assessment. Environmental Health Perspectives, 2011, 119, 1766-1774.	2.8	32
30	Global Gene Expression Profiling of a Population Exposed to a Range of Benzene Levels. Environmental Health Perspectives, 2011, 119, 628-640.	2.8	94
31	Estimating the Global Public Health Implications of Electricity and Coal Consumption. Environmental Health Perspectives, 2011, 119, 821-826.	2.8	29
32	Approaches for Assessing Risks to Sensitive Populations: Lessons Learned from Evaluating Risks in the Pediatric Population. Toxicological Sciences, 2010, 113, 4-26.	1.4	36
33	What Role for Biologically Based Dose–Response Models in Estimating Low-Dose Risk?. Environmental Health Perspectives, 2010, 118, 585-588.	2.8	40
34	Employing a Mechanistic Model for the Mapk Pathway to Examine the Impact of Cellular all or None Behavior on Overall Tissue Response. Dose-Response, 2010, 8, dose-response.0.	0.7	2
35	Expression and function of 5-hydroxytryptamine 4 receptors in smooth muscle preparations from the duodenum, ileum, and pelvic flexure of horses without gastrointestinal tract disease. American Journal of Veterinary Research, 2010, 71, 1432-1442.	0.3	10
36	A Discrete Time Model for the Analysis of Medium-Throughput C. elegans Growth Data. PLoS ONE, 2009, 4, e7018.	1.1	23

#	Article	IF	Citations
37	Dose-Response Modeling of High-Throughput Screening Data. Journal of Biomolecular Screening, 2009, 14, 1216-1227.	2.6	22
38	Tackling the Research Challenges of Health and Climate Change. Environmental Health Perspectives, 2009, 117, A534.	2.8	3
39	4 Toxicological decision-making on hazards and risks – status quo and way forward. Human and Experimental Toxicology, 2009, 28, 123-125.	1.1	1
40	AhR-mediated gene expression in the developing mouse telencephalon. Reproductive Toxicology, 2009, 28, 321-328.	1.3	29
41	Genetic and environmental pathways to complex diseases. BMC Systems Biology, 2009, 3, 46.	3.0	65
42	Expression and function of 5-HT7 receptors in smooth muscle preparations from equine duodenum, ileum, and pelvic flexure. Research in Veterinary Science, 2009, 87, 292-299.	0.9	13
43	Choosing the right path: enhancement of biologically relevant sets of genes or proteins using pathway structure. Genome Biology, 2009, 10, R44.	13.9	36
44	Building a Framework to Identify Global Health Impacts of Power Generation Systems. Epidemiology, 2009, 20, S263.	1.2	1
45	Application of a Mathematical Model to Describe the Effects of Chlorpyrifos on Caenorhabditis elegans Development. PLoS ONE, 2009, 4, e7024.	1.1	46
46	Characterization of the proneural gene regulatory network during mouse telencephalon development. BMC Biology, 2008, 6, 15.	1.7	95
47	Uncertainties in Biologicallyâ€Based Modeling of Formaldehydeâ€Induced Respiratory Cancer Risk: Identification of Key Issues. Risk Analysis, 2008, 28, 907-923.	1.5	13
48	Stereoselective biotransformation of ketamine in equine liver and lung microsomes. Journal of Veterinary Pharmacology and Therapeutics, 2008, 31, 446-455.	0.6	25
49	MtBE and cancer in animals: Statistical issues with poly-3 survival adjustments for lifetime studies. Regulatory Toxicology and Pharmacology, 2008, 50, 428-429.	1.3	3
50	In vitro effects of bethanechol on smooth muscle preparations from abomasal fundus, corpus, and antrum of dairy cows. Research in Veterinary Science, 2008, 84, 444-451.	0.9	5
51	Discussion and summary. Radiation Protection Dosimetry, 2008, 132, 273-274.	0.4	16
52	Meeting Report: Moving Upstreamâ€"Evaluating Adverse Upstream End Points for Improved Risk Assessment and Decision-Making. Environmental Health Perspectives, 2008, 116, 1568-1575.	2.8	68
53	Compound Cytotoxicity Profiling Using Quantitative High-Throughput Screening. Environmental Health Perspectives, 2008, 116, 284-291.	2.8	232
54	Health, Economy, and Environment: Sustainable Energy Choices for a Nation. Environmental Health Perspectives, 2008, 116, A236-7.	2.8	10

#	Article	IF	Citations
55	Characterizing Uncertainty and Variability in Physiologically Based Pharmacokinetic Models: State of the Science and Needs for Research and Implementation. Toxicological Sciences, 2007, 99, 395-402.	1.4	122
56	In vitro effects of bethanechol on specimens of intestinal smooth muscle obtained from the duodenum and jejunum of healthy dairy cows. American Journal of Veterinary Research, 2007, 68, 313-322.	0.3	5
57	The Forest for the Trees: A Systems Approach to Human Health Research. Environmental Health Perspectives, 2007, 115, 1261-1263.	2.8	17
58	Absolute estimation of initial concentrations of amplicon in a real-time RT-PCR process. BMC Bioinformatics, 2007, 8, 409.	1.2	19
59	Filling the Translation–Policy Gap. Environmental Health Perspectives, 2007, 115, A125-A125.	2.8	1
60	Report of an ISRTP Workshop: Progress and barriers to incorporating alternative toxicological methods in the U.S Regulatory Toxicology and Pharmacology, 2006, 46, 18-22.	1.3	24
61	Gene interaction network analysis suggests differences between high and low doses of acetaminophen. Toxicology and Applied Pharmacology, 2006, 215, 306-316.	1.3	23
62	Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion. Toxicology and Applied Pharmacology, 2006, 216, 373-386.	1.3	50
63	Benchmark Dose Approach. Wiley Series in Probability and Statistics, 2006, , 239-254.	0.0	12
64	Pesticide Testing on Humans: Resnick and Portier Respond. Environmental Health Perspectives, 2005, 113, .	2.8	0
65	Dose-Response Modeling for 2,3,7,8-Tetrachlorodibenzo-p-Dioxin. , 2005, , 247-298.		0
66	Pesticide Testing on Human Subjects: Weighing Benefits and Risks. Environmental Health Perspectives, 2005, 113, 813-817.	2.8	28
67	Dose-Additive Carcinogenicity of a Defined Mixture of "Dioxin-like Compounds― Environmental Health Perspectives, 2005, 113, 43-48.	2.8	110
68	Variation in the Hepatic Gene Expression in Individual Male Fischer Rats. Toxicologic Pathology, 2005, 33, 102-110.	0.9	14
69	The NIEHS and the National Toxicology Program: An Integrated Scientific Vision. Environmental Health Perspectives, 2005, 113, A440-A440.	2.8	3
70	Pesticide Testing on Humans: Resnick and Portier Respond. Environmental Health Perspectives, 2005, 113, A805-A805.	2.8	0
71	Gene Interaction Network Suggests Dioxin Induces a Significant Linkage between Aryl Hydrocarbon Receptor and Retinoic Acid Receptor Beta. Environmental Health Perspectives, 2004, 112, 1217-1224.	2.8	31
72	Human consumption of methyleugenol and its elimination from serum Environmental Health Perspectives, 2004, 112, 678-680.	2.8	31

#	Article	IF	CITATIONS
73	The TAO-Gen Algorithm for Identifying Gene Interaction Networks with Application to SOS Repair inE. coli. Environmental Health Perspectives, 2004, 112, 1614-1621.	2.8	18
74	Extended Histopathology in Immunotoxicity Testing: Interlaboratory Validation Studies. Toxicological Sciences, 2004, 78, 107-115.	1.4	56
75	The Accuracy of Extended Histopathology to Detect Immunotoxic Chemicals. Toxicological Sciences, 2004, 82, 504-514.	1.4	55
76	Human Carcinogenic Risk Evaluation, Part V: The National Toxicology Program Vision for Assessing the Human Carcinogenic Hazard of Chemicals. Toxicological Sciences, 2004, 82, 363-366.	1.4	40
77	Application of a Statistical Dynamic Model Investigating the Short-Term Cellular Kinetics Induced by Riddelliine, a Hepatic Endothelial Carcinogen. Toxicological Sciences, 2004, 80, 258-267.	1.4	2
78	Evaluation of toxic equivalency factors for induction of cytochromes P450 CYP1A1 and CYP1A2 enzyme activity by dioxin-like compounds. Toxicology and Applied Pharmacology, 2004, 194, 156-168.	1.3	63
79	Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration. Toxicology and Applied Pharmacology, 2004, 195, 113-125.	1.3	22
80	NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of methanol. Reproductive Toxicology, 2004, 18, 303-390.	1.3	33
81	The TAO-Gen Algorithm for Identifying Gene Interaction Networks with Application to SOS Repair in E. coli. Environmental Health Perspectives, 2004, 112, 1614-1621.	2.8	16
82	Development of a biologically-based controlled growth and differentiation model for developmental toxicology. Journal of Mathematical Biology, 2003, 46, 1-16.	0.8	7
83	Toxicity characterization of environmental chemicals by the US National Toxicology Program: an overview. International Journal of Hygiene and Environmental Health, 2003, 206, 437-445.	2.1	24
84	Temperature, air pollution, and hospitalization for cardiovascular diseases among elderly people in Denver Environmental Health Perspectives, 2003, 111, 1312-1317.	2.8	267
85	Inhibition of Human and Pig Ureter Motility in Vitro and in Vivo by the K+ Channel Openers PKF 217-744b and Nicorandil. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 651-658.	1.3	27
86	A Controlled Growth and Differentiation Model for Non-Monotonic Responses. Human and Ecological Risk Assessment (HERA), 2002, 8, 1739-1755.	1.7	3
87	Toxicogenomics: the new frontier in risk analysis. Carcinogenesis, 2002, 23, 903-905.	1.3	53
88	Pharmacokinetics of Sodium Nitrite-Induced Methemoglobinemia in the Rat. Drug Metabolism and Disposition, 2002, 30, 676-683.	1.7	77
89	Impact of Physiologically Based Pharmacokinetic Modeling on Benchmark Dose Calculations for TCDD-Induced Biochemical Responses. Regulatory Toxicology and Pharmacology, 2002, 36, 287-296.	1.3	13
90	The association between biomarker-based exposure estimates for phthalates and demographic factors in a human reference population Environmental Health Perspectives, 2002, 110, 405-410.	2.8	72

#	Article	IF	Citations
91	Effects of ketanserin and DOI on spontaneous and 5-HT-evoked peristalsis of the pig ureter in vivo. British Journal of Pharmacology, 2002, 135, 1026-1032.	2.7	13
92	A Physiologically Based Pharmacokinetic Model of p,p′-Dichlorodiphenylsulfone. Toxicology and Applied Pharmacology, 2002, 181, 153-163.	1.3	10
93	Endocrine dismodulation and cancer. Neuroendocrinology Letters, 2002, 23 Suppl 2, 43-7.	0.2	7
94	Comments on the International Symposium on Light, Endocrine Systems and Cancer. Neuroendocrinology Letters, 2002, 23 Suppl 2, 79-81.	0.2	2
95	Physiological modeling of a proposed mechanism of enzyme induction by TCDD. Toxicology, 2001, 162, 193-208.	2.0	26
96	Linking toxicology and epidemiology: the role of mechanistic modelling. Statistics in Medicine, 2001, 20, 1387-1393.	0.8	1
97	A Physiologically Based Pharmacokinetic Model for Inhalation and Intravenous Administration of Naphthalene in Rats and Mice. Toxicology and Applied Pharmacology, 2001, 176, 81-91.	1.3	32
98	Identification of a Cardiac Sodium Channel Insensitive to Synthetic Modulators. Journal of Cardiovascular Pharmacology and Therapeutics, 2001, 6, 201-212.	1.0	3
99	Calculation of the Cumulative Distribution Function of the Time to a Small Observable Tumor. Bulletin of Mathematical Biology, 2000, 62, 229-240.	0.9	10
100	Multistage, stochastic models of the cancer process: A general theory for calculating tumor incidence. Stochastic Environmental Research and Risk Assessment, 2000, 14, 173-179.	1.9	16
101	Human exposure estimates for phthalates Environmental Health Perspectives, 2000, 108, A440-2.	2.8	218
102	COMMENTS ON A BIOCHEMICAL MODEL OF CYCLOPHOSPHAMIDE HEMATOTOXICITY. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2000, 61, 525-528.	1.1	0
103	Risk ranges for various endpoints following exposure to 2,3,7,8-TCDD. Food Additives and Contaminants, 2000, 17, 335-346.	2.0	9
104	Induction of Lung Lesions in Female Rats Following Chronic Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. Toxicologic Pathology, 2000, 28, 761-769.	0.9	22
105	Incorporating observability thresholds of tumors into the two-stage carcinogenesis model. Mathematical Biosciences, 2000, 163, 75-89.	0.9	6
106	Multiple organ carcinogenicity of inhaled chloroprene (2-chloro-1,3-butadiene) in F344/N rats and B6C3F1 mice and comparison of dose–response with 1,3-butadiene in mice. Carcinogenesis, 1999, 20, 867-878.	1.3	47
107	Characterization of the Dose–Response of CYP1B1, CYP1A1, and CYP1A2 in the Liver of Female Sprague–Dawley Rats Following Chronic Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. Toxicology and Applied Pharmacology, 1999, 154, 279-286.	1.3	88
108	Effects of Glutathione Transferase Theta Polymorphism on the Risk Estimates of Dichloromethane to Humans. Toxicology and Applied Pharmacology, 1999, 158, 221-230.	1.3	64

#	Article	IF	Citations
109	Replication Potential of Cells via the Protein Kinase C-MAPK pathway: Application of a Mathematical Model. Bulletin of Mathematical Biology, 1999, 61, 379-398.	0.9	15
110	Quantitative Mechanistically Based Dose-Response Modeling with Endocrine-Active Compounds. Environmental Health Perspectives, 1999, 107, 631.	2.8	3
111	Using Structural Information to Create Physiologically Based Pharmacokinetic Models for all Polychlorinated Biphenyls. Toxicology and Applied Pharmacology, 1998, 151, 110-116.	1.3	26
112	Eyes Closed: Simple, Intuitive, Statistically Sound, and Efficient Methods for Estimating Parameters of Clonal Growth Cancer Models. Risk Analysis, 1998, 18, 529-534.	1.5	4
113	Characterizing Dose-Response I: Critical Assessment of the Benchmark Dose Concept. Risk Analysis, 1998, 18, 13-26.	1.5	53
114	A model for hepatocarcinogenesis treating phenotypical changes in focal hepatocellular lesions as epigenetic events. Mathematical Biosciences, 1998, 148, 181-204.	0.9	26
115	Immunologic Findings in Workers Formerly Exposed to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin and Its Congeners. Environmental Health Perspectives, 1998, 106, 689.	2.8	0
116	Genetic susceptibility: significance in risk assessment. Toxicology Letters, 1998, 102-103, 185-189.	0.4	9
117	U-shaped dose-response curves for carcinogens. Human and Experimental Toxicology, 1998, 17, 705-707.	1.1	4
118	U-shaped dose-response curves for carcinogens. Human and Experimental Toxicology, 1998, 17, 705-707.	1,1	1
119	Statistical research needs in mechanistic modelling for carcinogenic risk assessment. Statistical Methods in Medical Research, 1997, 6, 305-315.	0.7	10
120	The Two-Stage Model of Carcinogenesis: Overcoming the Nonidentifiability Dilemma. Risk Analysis, 1997, 17, 367-374.	1.5	8
121	Evaluation of Chemicals with Endocrine Modulating Activity in a Yeast-Based Steroid Hormone Receptor Gene Transcription Assay. Toxicology and Applied Pharmacology, 1997, 143, 205-212.	1.3	635
122	Using Structural Information to Create Physiologically Based Pharmacokinetic Models for All Polychlorinated Biphenyls. Toxicology and Applied Pharmacology, 1997, 144, 340-347.	1.3	82
123	A Mathematical Model of Production, Distribution, and Metabolism of Melatonin in Mammalian Systems. Toxicology and Applied Pharmacology, 1997, 147, 83-92.	1.3	10
124	Implications for Risk Assessment of Suggested Nongenotoxic Mechanisms of Chemical Carcinogenesis. Environmental Health Perspectives, 1996, 104, 123.	2.8	28
125	Stochastic simulation of a multistage model of carcinogenesis. Mathematical Biosciences, 1996, 134, 35-50.	0.9	8
126	Calculating tumor incidence rates in stochastic models of carcinogenesis. Mathematical Biosciences, 1996, 135, 129-146.	0.9	35

#	Article	IF	CITATIONS
127	A Mechanistic Model of Effects of Dioxin on Thyroid Hormones in the Rat. Toxicology and Applied Pharmacology, 1996, 136, 29-48.	1.3	85
128	Modeling the Number and Size of Hepatic Focal Lesions Following Exposure to 2,3,7,8-TCDD. Toxicology and Applied Pharmacology, 1996, 138, 20-30.	1.3	48
129	Quantitative analysis of multiple phenotype enzyme-altered foci in rat hepatocarcinogenesis experiments: the multipath/multistage model. Carcinogenesis, 1995, 16, 2499-2506.	1.3	12
130	Carcinoma formation in NMRI mouse skin painting studies is a process suggesting greater than two stages. Carcinogenesis, 1995, 16, 53-59.	1.3	23
131	Nonlinearity of dose-response functions for carcinogenicity Environmental Health Perspectives, 1994, 102, 109-113.	2.8	37
132	Biostatistical issues in the design and analysis of animal carcinogenicity experiments Environmental Health Perspectives, 1994, 102, 5-8.	2.8	22
133	Use of animal studies in risk assessment for immunotoxicology. Toxicology, 1994, 92, 229-243.	2.0	34
134	The Importance of Biological Realism in Dioxin Risk Assessment Models Michael. Risk Analysis, 1994, 14, 993-1000.	1.5	14
135	Multistage Models of Carcinogenesis: An Approximation for the Size and Number Distribution of Late-Stage Clones. Risk Analysis, 1994, 14, 1039-1048.	1.5	14
136	The Exact Formula for Tumor Incidence in the Two-Stage Model. Risk Analysis, 1994, 14, 1079-1080.	1.5	60
137	The use of animal tests in risk assessment for immunotoxicology. Toxicology in Vitro, 1994, 8, 945-950.	1.1	5
138	A stem cell model for carcinogenesis. Mathematical Biosciences, 1994, 120, 211-232.	0.9	13
139	Potential Effects of Chemical Mixtures on the Carcinogenic Process within the Context of the Mathematical Multistage Model. , 1994, , 665-686.		5
140	Effects of the Mechanism of Receptor-Mediated Gene Expression on the Shape of the Dose-Response Curve. Risk Analysis, 1993, 13, 565-572.	1.5	25
141	Mechanistic Modelling and Risk Assessment. Basic and Clinical Pharmacology and Toxicology, 1993, 72, 28-32.	0.0	4
142	A Mechanistic Model of Effects of Dioxin on Gene Expression in the Rat Liver. Toxicology and Applied Pharmacology, 1993, 120, 138-154.	1.3	115
143	An Evaluation of Some Methods for Fitting Dose-Response Models to Quantal-Response Developmental Toxicology Data. Biometrics, 1993, 49, 779.	0.8	31
144	A Measure of Tumorigenic Potency Incorporating Dose-Response Shape. Biometrics, 1993, 49, 917.	0.8	17

#	Article	IF	CITATIONS
145	Cell Proliferation and Chemical Carcinogenesis: Symposium Overview. Environmental Health Perspectives, 1993, 101, 3.	2.8	2
146	Using Cell Replication Data in Mathematical Modeling in Carcinogenesis. Environmental Health Perspectives, 1993, 101, 79.	2.8	4
147	Risk Assessment in Immunotoxicology. Toxicological Sciences, 1993, 21, 71-82.	1.4	11
148	An Index of Tumorigenic Potency. Biometrics, 1993, 49, 357.	0.8	7
149	Birth and death/differentiation rates of papillomas in mouse skin. Carcinogenesis, 1992, 13, 973-978.	1.3	42
150	Explicit solutions for constrained maximum likelihood estimators in survival/sacrifice experiments. Biometrika, 1992, 79, 717-729.	1.3	9
151	Risk Assessment in Immunotoxicology. Toxicological Sciences, 1992, 18, 200-210.	1.4	19
152	Analytic expressions for maximum likelihood estimators in a nonparametric model of tumor incidence and death. Communications in Statistics - Theory and Methods, 1992, 21, 711-732.	0.6	20
153	Qualitative and quantitative experimental models to aid in risk assessment for immunotoxicology. Toxicology Letters, 1992, 64-65, 71-78.	0.4	47
154	Uncertainty in physiological pharmacokinetic modeling and its impact on statistical risk estimation of 2,3,7,8 TCDD. Chemosphere, 1992, 25, 239-242.	4.2	4
155	Concordance of Carcinogenic Response between Rodent Species: Potency Dependence and Potential Underestimation. Risk Analysis, 1992, 12, 115-121.	1.5	18
156	Should the presence of carcinogens in breast milk discourage breast feeding?. Regulatory Toxicology and Pharmacology, 1991, 13, 228-240.	1.3	35
157	The application of a multistage model that incorporates DNA damage and repair to the analysis of initiation/promotion experiments. Mathematical Biosciences, 1991, 105, 139-166.	0.9	29
158	An Evaluation of the Rai and Van Ryzin Dose-Response Model in Teratology. Risk Analysis, 1991, 11, 111-120.	1.5	14
159	A Multistage Model of Carcinogenesis Incorporating DNA Damage and Repair. Risk Analysis, 1991, 11, 535-543.	1.5	47
160	Distinguishing between Models of Carcinogenesis: The Role of Clonal Expansion. Toxicological Sciences, 1991, 17, 601-613.	1.4	0
161	A note on fitting one-compartment models: Non-linear least squares versus linear least squares using transformed data. Journal of Applied Toxicology, 1990, 10, 303-306.	1.4	7
162	Two-Stage Models of Carcinogenesis, Classification of Agents, and Design of Experiments. Toxicological Sciences, 1990, 14, 444-460.	1.4	0

#	Article	IF	CITATIONS
163	Variability of Safe Dose Estimates When Using Complicated Models of the Carcinogenic Process. Toxicological Sciences, 1989, 13, 533-544.	1.4	O
164	Twoâ€stage models of tumor incidence for historical control animals in the national toxicology program's carcinogenicity experiments. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1989, 27, 21-45.	1,1	14
165	Testing for Increased Carcinogenicity Using a Survival-Adjusted Quantal Response Test. Toxicological Sciences, 1989, 12, 731-737.	1.4	3
166	A Note on Approximating the Cumulative Distribution Function of the Time to Tumor Onset in Multistage Models. Biometrics, 1989, 45, 1259.	0.8	13
167	An illustration of dangers of ignoring survival differences in carcinogenic data. Journal of Applied Toxicology, 1988, 8, 185-189.	1.4	7
168	Species Correlation of Chemical Carcinogens. Risk Analysis, 1988, 8, 551-553.	1.5	5
169	Effects of Treatment-Induced Mortality and Tumor-Induced Mortality on Tests for Carcinogenicity in Small Samples. Biometrics, 1988, 44, 417.	0.8	242
170	Life Table Analysis of Carcinogenicity Experiments. Journal of the American College of Toxicology, 1988, 7, 575-582.	0.2	1
171	Semiparametric Analysis of Tumor Incidence Rates in Survival/Sacrifice Experiments. Biometrics, 1987, 43, 107.	0.8	39
172	Simulating failure times when the event of interest is unobservable with emphasis on animal carcinogenicity studies. Journal of Biomedical Informatics, 1987, 20, 458-466.	0.7	8
173	Issues Concerning the Estimation of the TD50. Risk Analysis, 1987, 7, 437-447.	1.5	22
174	The Impact of Litter Effects on Dose-Response Modeling in Teratology. Biometrics, 1986, 42, 85.	0.8	170
175	Type 1 Error and Power of the Linear Trend Test in Proportions under the National Toxicology Program's Modified Pathology Protocol. Toxicological Sciences, 1986, 6, 515-519.	1.4	O
176	Estimating the tumour onset distribution in animal carcinogenesis experiments. Biometrika, 1986, 73, 371-378.	1.3	38
177	Type 1 error of trend tests in proportions and the design of cancer screens. Communications in Statistics - Theory and Methods, 1984, 13, 1-14.	0.6	35
178	Design of Animal Carcinogenicity Studies for Goodness-of-Fit of Multistage Models. Toxicological Sciences, 1984, 4, 949-959.	1.4	0
179	Low-Dose-Rate Extrapolation Using the Multistage Model. Biometrics, 1983, 39, 897.	0.8	44